Tempest Therapeutics, Inc. (TPST) Key Metrics
TPST valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.5M
- Enterprise value
- $22.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 22.9 10-yr median 15.8
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- −1.71
TPST key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTPST valuation Price multiples at each fiscal year-end price.
TPST returns How much profit the business earns on the capital it uses.
TPST per-share figures Results divided by the shares outstanding at year-end.
TPST financial health Debt, liquidity and how easily interest is covered.
TPST valuation history
TPST returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TPST debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TPST price vs earnings per share
TPST key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $11.9M | $302.7M | $881.8M | — | — | — | — | — | — | — |
| Enterprise value | $12.3M | $287.8M | $863.2M | — | — | — | — | — | — | — |
| Price / book | 1.8 | 15.8 | 32.9 | — | — | — | — | — | — | — |
| Earnings yield | −220.5% | −13.8% | −3.3% | — | — | — | — | — | — | — |
| Free cash flow yield | −225.2% | −11.1% | −3.1% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.87 | $10.85 | $57.20 | $14.95 | $68.64 | $417.30 | $1,314.30 | $1,550.25 | $4,095.00 | $4,475.25 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Earnings per share | −$6.33 | −$1.50 | −$1.91 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$6.46 | −$1.18 | −$1.77 | — | — | — | — | — | — | — |
| Free cash flow per share | −$6.46 | −$1.20 | −$1.79 | — | — | — | — | — | — | — |
| Cash per share | $1.86 | $1.08 | $2.54 | — | — | — | — | — | — | — |
| Book value per share | $1.61 | $0.69 | $1.74 | — | — | — | — | — | — | — |
| Tangible book value per share | $1.61 | $0.69 | $1.74 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.02 | $0.01 | — | — | — | — | — | — | — |
| Debt per share | $1.96 | $0.55 | $1.34 | — | — | — | — | — | — | — |
| Shares outstanding | 4.1M | 27.9M | 15.4M | — | — | — | — | — | — | — |
| Change in shares outstanding | −85.1% | +81.0% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −203.6% | −182.3% | −131.4% | −131.7% | — | — | −68.8% | −74.3% | −153.2% | −70.0% |
| Return on invested capital (ROIC) | −370.8% | −534.5% | −267.9% | −463.0% | — | — | — | — | — | — |
| Return on assets (ROA) | −89.9% | −89.9% | −60.4% | −59.9% | −58.9% | −39.1% | −56.0% | −52.3% | −118.8% | −63.0% |
| Return on tangible assets | −155.1% | −100.9% | −57.1% | −77.5% | −38.6% | −83.6% | −59.4% | −32.3% | −426.9% | −67.1% |
| Financial health | ||||||||||
| Total debt | $8.1M | $15.4M | $20.7M | $22.1M | $18.5M | $2.4M | $4.5M | $572,000 | $773,000 | — |
| Cash & short-term investments | $7.7M | $30.3M | $39.2M | $31.2M | $51.8M | $18.8M | $63.5M | $77.7M | $67.2M | $114.4M |
| Net debt | $434,000 | −$14.9M | −$18.6M | −$9.1M | −$33.3M | −$16.4M | −$59.0M | −$77.1M | −$66.4M | −$114.4M |
| Debt / equity | 1.22 | 0.80 | 0.77 | 1.22 | 0.51 | — | 0.08 | 0.01 | 0.35 | — |
| Debt / assets | 0.48 | 0.37 | 0.40 | 0.48 | 0.25 | 0.11 | 0.06 | 0.01 | 0.04 | — |
| Current ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 | 6.15 | 5.68 | 8.50 | 4.82 | 8.82 |
| Quick ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.36 | 5.94 | 5.68 | 8.50 | 4.82 | 8.82 |
| Interest coverage | -128.4 | -31.9 | -20.1 | -21.4 | -21.0 | -38.1 | -43.7 | -172.5 | — | -122.9 |
| Working capital | $5.0M | $17.3M | $31.0M | $25.7M | $48.9M | $16.6M | $58.6M | $73.6M | $15.6M | $103.2M |
| Invested capital | $7.1M | $4.2M | $8.2M | $9.0M | $2.8M | −$85.2M | −$443,000 | −$6.2M | −$64.2M | −$6.2M |
| Tangible asset value | $6.7M | $19.1M | $26.8M | $18.1M | $36.1M | −$68.8M | $59.9M | $73.1M | $15.0M | $108.2M |
| Net current asset value | −$2.0M | $9.1M | $15.5M | $5.0M | $31.8M | −$71.8M | $56.0M | $72.5M | $14.9M | $102.1M |
| Graham net-net per share | −$0.62 | $0.28 | $0.93 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / revenue | — | — | — | — | — | — | — | — | 1.4% | 396.0% |
| Capex / depreciation | 0.00 | 1.12 | 0.45 | 0.88 | 0.36 | 0.15 | 0.38 | 1.12 | 0.14 | 1.16 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | — | 2,336.6% | 1,411.2% |
| R&D / revenue | — | — | — | — | — | — | — | — | 4,924.1% | 3,314.1% |
| SG&A / revenue | — | — | — | — | — | — | — | — | 9,404.7% | 7,538.0% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | 1,275.6 | — |
| Days of inventory on hand | — | — | — | — | 325.8 | 307.2 | — | — | 0.0 | — |
| Days payables outstanding | — | 1,545.9 | 935.5 | 211.2 | 296.3 | 574.6 | 606.0 | 24,181.2 | 28,841.5 | 187.0 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | -27,565.9 | — |
| Receivables turnover | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | — |
| Payables turnover | — | 0.24 | 0.39 | 1.73 | 1.23 | 0.64 | 0.60 | 0.02 | 0.01 | 1.95 |
| Inventory turnover | — | — | — | — | 1.12 | 1.19 | — | — | 28,000.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Average receivables | — | — | — | $7.7M | $7.6M | $768,000 | $1.8M | $1.7M | $1.0M | — |
| Average payables | $1.7M | $1.6M | $976,500 | $1.0M | $1.0M | $1.3M | $1.7M | $2.1M | $2.2M | $2.8M |
| Average inventory | — | — | — | — | $1.1M | $686,000 | — | — | $1 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TPST's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TPST valuation and financial ratios
Tempest Therapeutics earned a return on equity of −203.6% and a return on invested capital of −370.8% in fiscal 2025. It ended the year with $8.1 million of debt and $7.7 million in cash and short-term investments, net debt of $0.4 million.
See the TPST income statement, the TPST chart for price history, or the TPST stock overview for the latest quote and news.
TPST key metrics FAQ
What is Tempest Therapeutics's return on equity?
Tempest Therapeutics's return on equity (ROE) was −203.6% in fiscal 2025: net income of -$26.3 million on average shareholders' equity of $12.9 million.
What is Tempest Therapeutics's ROIC?
Tempest Therapeutics's return on invested capital was −370.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Tempest Therapeutics have?
Tempest Therapeutics had total debt of $8.1 million at the end of fiscal 2025, a debt-to-equity ratio of 1.22.
What is Tempest Therapeutics's free cash flow yield?
Tempest Therapeutics generated -$26.8 million of free cash flow in fiscal 2025, a free cash flow yield of −225.2% on its market value at year-end ($11.9 million).
What is Tempest Therapeutics's current ratio?
Tempest Therapeutics's current ratio was 2.50 at the end of fiscal 2025: current assets were 2.50 times current liabilities.